Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels

Reinhilde Mlekusch1, Christian Humpel

  • 1Laboratory of Psychiatry and Experimental Alzheimers Research, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria.

Neuroscience Letters
|September 30, 2009
PubMed

Insights

Matrix metalloproteinases (MMPs) are crucial in brain health. This study found decreased MMP-2 and MMP-3 levels in cerebrospinal fluid linked to lower beta-amyloid, suggesting their role in Alzheimer's disease pathology.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Matrix metalloproteinases (MMPs) are enzymes that degrade extracellular matrix proteins.
  • MMPs are increasingly implicated in neurodegenerative diseases such as Alzheimer's disease (AD), vascular dementia (VD), and Parkinson's disease (PD).

Purpose of the Study:

  • To analyze eight matrix metalloproteinases (MMP-1, -2, -3, -7, -8, -9, -10, -13) in human cerebrospinal fluid (CSF).
  • To correlate MMP levels with established Alzheimer's disease biomarkers: beta-amyloid(1-42) (Abeta), total-tau, and phospho-tau-181.

Main Methods:

  • Analysis of eight MMPs in human CSF samples.
  • Correlation analysis between MMP levels and Abeta, total-tau, and phospho-tau-181 concentrations.

Main Results:

  • Significant decrease in MMP-2 and MMP-3 levels observed in CSF samples with reduced Abeta levels.
  • MMP-2 and MMP-3 levels showed a significant inverse correlation with Abeta concentrations.

Conclusions:

  • MMP-2 and MMP-3 are directly linked to beta-amyloid processing in the brain.
  • Dysfunction of MMP-2 and MMP-3 may play a role in the pathogenesis of Alzheimer's disease by influencing Abeta metabolism.